This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
by Zacks Equity Research
Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.
Here's Why You Should Invest in Adverum (ADVM) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.
Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
by Zacks Equity Research
Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.
Here's Why You Should Invest in Aquestive (AQST) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.
Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?
by Zacks Equity Research
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
by Zacks Equity Research
Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
by Ahan Chakraborty
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Best Momentum Stock to Buy for December 7th
by Zacks Equity Research
AQST and VVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 7, 2023.
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene
by Zacks Equity Research
Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.
Journey Medical (DERM) Up on Update for Skin Disease Candidate
by Zacks Equity Research
Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.
Best Momentum Stocks to Buy for December 1st
by Zacks Equity Research
LEU, AQST and TM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 1, 2023.
New Strong Buy Stocks for December 1st
by Zacks Equity Research
AQST, TM, LEU, BWAY and MOD have been added to the Zacks Rank #1 (Strong Buy) List on December 1, 2023.
Aquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Best Momentum Stocks to Buy for November 28th
by Zacks Equity Research
AQST, FMX and MNSO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 28, 2023.
New Strong Buy Stocks for November 28th
by Zacks Equity Research
AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.
Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should Know
by Zacks Equity Research
Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year.
New Strong Buy Stocks for November 21st
by Zacks Equity Research
AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.
Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for November 16th
by Zacks Equity Research
IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.
Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $1.43, denoting a +1.42% change from the preceding trading day.